Compare American Electric Power Company Inc (AEP) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs BioNano Genomics Inc — how do they compare? American Electric Power Company Inc trades at $123.7 (market cap $67.28B), while BioNano Genomics Inc trades at $1.17 (market cap $13.66M). The key difference: American Electric Power Company Inc is far larger — about 4925.3× BioNano Genomics Inc's market cap, and American Electric Power Company Inc pays a 3.07% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| AEP | BNGO | |
|---|---|---|
Market Cap | $67.28B | $13.66M |
Sector | Utilities | Health |
52-Week High | $138.69 | $4.92 |
52-Week Low | $106.44 | $1.06 |
Enterprise Value | $120.17B | $16.26M |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $122.84, down 2.3% on the day, with a bearish technical signal. Recent Q2 2026 earnings missed estimates at $1.36 per share versus $1.48 expected, though revenue grew 7% year-over-year. The company raised full-year 2026 operating EPS guidance to $6.25–$6.55, supported by 69 GW of contracted load and a $78 billion capital plan. Analyst consensus remains strongly bullish with a $140.89 price target and no sell ratings.
The outlook is positive due to robust demand from data centers and infrastructure growth, but risks include high capital expenditures and interest expenses. Valuation metrics like a P/E of 21.42 are elevated, requiring sustained earnings growth to justify. The stock offers a stable dividend, with the next payment of $0.95 ex-dividend on August 10, 2026.
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
